Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Avidity Biosciences Inc shares valued at $657,694 were sold by Flanagan W. Michael on Jun 11 ’25. At $32.88 per share, Flanagan W. Michael sold 20,000 shares. The insider’s holdings dropped to 80,195 shares worth approximately $2.58 million following the completion of this transaction.
Also, WILLIAM MICHAEL FLANAGAN purchased 20,000 shares, netting a total of over 672,400 in proceeds.
Before that, Gallagher Kathleen P. had sold 5,875 shares from its account. In a trade valued at $190,833, the Chief Program Officer traded Avidity Biosciences Inc shares for $32.48 each. Upon closing the transaction, the insider’s holdings decreased to 5,875 shares, worth approximately $1.62 million.
As published in their initiating research note from Raymond James on June 11, 2025, Avidity Biosciences Inc [RNA] has been a Strong buy and the price target has been revised to $65. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in mid March. As of March 12, 2025, BMO Capital Markets has initiated its “an Outperform” rating for RNA. Earlier on March 07, 2025, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for RNA stock.
Analyzing RNA Stock Performance
On last trading session,, Avidity Biosciences Inc [NASDAQ: RNA] rose 0.41% to $32.14. The stock’s lowest price that day was $31.41, but it reached a high of $32.48 in the same session. During the last five days, there has been a drop of approximately -9.69%. Over the course of the year, Avidity Biosciences Inc shares have jumped approximately 10.52%.
Support And Resistance Levels for Avidity Biosciences Inc (RNA)
RSI (Relative Strength Index) is 51.12 on the 14-day chart, showing neutral technical sentiment.
Is Avidity Biosciences Inc subject to short interest?
Stocks of Avidity Biosciences Inc saw a sharp rise in short interest on 2025-05-30 jumping by 0.59 million shares to 16.17 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 15.58 million shares. A jump of 3.65% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 12.13 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.13.
Which companies own the most shares of Avidity Biosciences Inc (RNA)?
In terms of Avidity Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 54.5 in the next 12 months, up nearly 70.26% from the previous closing price of $32.01. Analysts anticipate Avidity Biosciences Inc stock to reach 59 by 2025, with the lowest price target being 50. In spite of this, 6 analysts ranked Avidity Biosciences Inc stock as Buy at the end of 2025. On December 20, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $72.
